Piper Sandler analyst Allison M. Bratzel raised the firm’s price target on MeiraGTx (MGTX) to $30 from $28 and keeps an Overweight rating on the shares following the news that the company has entered a broad strategic collaboration with Eli Lilly (LLY) to develop and commercialize genetic medicines in ophthalmology. This deal grants the latter worldwide exclusive rights to MeiraGTx’s AAVAIPL1 program in LCA4. In exchange, MeiraGTx receives an upfront payment of $75M and is eligible to receive over $400M in total milestone payments and tiered royalties on licensed products. Piper thinks this is a positive development for MeiraGTx, which not only helps validate the company’s technology, but provides non-dilutive capital through both upfront and milestone payments. The firm remains a buyer.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX:
- MeiraGTx enters strategic collaboration with Eli Lilly
- MeiraGTx and Eli Lilly Collaborate on Genetic Medicines
- MeiraGTx’s Gene Therapy Study for Xerostomia: A Promising Update
- MeiraGTx’s Gene Therapy Trial: A Potential Game-Changer for Radiation-Induced Xerostomia
- MeiraGTx initiated with a Strong Buy at Raymond James